The Pulse Check

Aug 7, 2026

•

2 min read

Day 2 of Bioshares: One Year On...

Jason Segal

The Pulse Check

Aug 6, 2026

•

1 min read

Eli Lilly's $23 Billion Shopping Spree

Jason Segal

The Pulse Check

Aug 5, 2026

•

1 min read

Day 1 of Bioshares: It’s Snow Problem

Jason Segal

The Pulse Check

Aug 4, 2026

•

8 min read

The Money Equation for Biotechs

Jason Segal

The Pulse Check

Aug 3, 2026

•

9 min read

Time is Brain: The EMVision Story (EMV)

Jason Segal

The Pulse Check

Control Bionics: A Quarter’s Worth of Progress

Jul 31, 2026

•

5 min read

Control Bionics: A Quarter’s Worth of Progress

Jason Segal

The Pulse Check

The Biggest Tree in Healthcare Stands Tall

Jul 30, 2026

•

2 min read

The Biggest Tree in Healthcare Stands Tall

Jason Segal

Emyria (ASX: EMD)

Jul 29, 2026

•

3 min read

The Human Side to Healthcare Investing

Jason Segal

The Pulse Check

Jul 28, 2026

•

12 min read

Armchair on stage at Bio Connections

Jason Segal

The Pulse Check

Deep Cuts from the Surgeon: What happened with EBR?

Jul 27, 2026

•

3 min read

Deep Cuts from the Surgeon: What happened with EBR?

Jason Segal

The Pulse Check

Jul 24, 2026

•

3 min read

FDA gives the green light to peptides

Jason Segal

The Pulse Check

Designer Genes: The PYC Therapeutics Story (PYC)

Jul 23, 2026

•

10 min read

Designer Genes: The PYC Therapeutics Story (PYC)

Jason Segal

The Pulse Check

Tetratherix (TTX) Quarterly: 4Cing a Big Year

Jul 22, 2026

•

4 min read

Tetratherix (TTX) Quarterly: 4Cing a Big Year

Jason Segal

The Pulse Check

The Guys Who Make Your TV Just Bet $1.8B on Peptides

Jul 21, 2026

•

3 min read

The Guys Who Make Your TV Just Bet $1.8B on Peptides

Jason Segal

The Pulse Check

Placebo Your Bets: Prediction Markets Enter Biotech

Jul 20, 2026

•

7 min read

Placebo Your Bets: Prediction Markets Enter Biotech

Jason Segal

Emyria (ASX: EMD)

Eli Lilly Enters Psychedelics: The Year of the Mushroom

Jul 17, 2026

•

5 min read

Eli Lilly Enters Psychedelics: The Year of the Mushroom

Jason Segal

The Pulse Check

Jul 16, 2026

•

8 min read

How CMC Makes or Breaks a Biotech

Jason Segal

Neurotech International (ASX: NTI)

The Long Way Round: The Neurotech International Story (NTI)

Jul 15, 2026

•

10 min read

The Long Way Round: The Neurotech International Story (NTI)

Jason Segal

The Pulse Check

Jul 14, 2026

•

3 min read

A Peptidal Wave is Coming

Jason Segal

The Pulse Check

Hamstrung No More: NeuroStrip’s Sporting Edge

Jul 13, 2026

•

9 min read

Hamstrung No More: NeuroStrip’s Sporting Edge

Jason Segal

The Pulse Check

Animal Rules: The Island Pharmaceuticals Story (ILA)

Jul 10, 2026

•

9 min read

Animal Rules: The Island Pharmaceuticals Story (ILA)

Jason Segal

The Pulse Check

Jul 9, 2026

•

1 min read

Launching Armchair After Market

Jason Segal

Emyria (ASX: EMD)

Compass Points North: Six-Month Psychedelic Data

Jul 8, 2026

•

3 min read

Compass Points North: Six-Month Psychedelic Data

Jason Segal

The Pulse Check

Jul 7, 2026

•

4 min read

The Capital Waterfall Starting to Flow?

Jason Segal

The Pulse Check

A Fox got into the Cash Box: The Genetic Signatures Story (GSS)

Jul 6, 2026

•

5 min read

A Fox got into the Cash Box: The Genetic Signatures Story (GSS)

Jason Segal

The Pulse Check

Day 2 of Bioshares: One Year On...

Eli Lilly's $23 Billion Shopping Spree

Day 1 of Bioshares: It’s Snow Problem

The Money Equation for Biotechs

Time is Brain: The EMVision Story (EMV)

Control Bionics: A Quarter’s Worth of Progress

The Biggest Tree in Healthcare Stands Tall

The Human Side to Healthcare Investing

Armchair on stage at Bio Connections

Deep Cuts from the Surgeon: What happened with EBR?

FDA gives the green light to peptides

Designer Genes: The PYC Therapeutics Story (PYC)

Tetratherix (TTX) Quarterly: 4Cing a Big Year

The Guys Who Make Your TV Just Bet $1.8B on Peptides

Placebo Your Bets: Prediction Markets Enter Biotech

Eli Lilly Enters Psychedelics: The Year of the Mushroom

How CMC Makes or Breaks a Biotech

The Long Way Round: The Neurotech International Story (NTI)

A Peptidal Wave is Coming

Hamstrung No More: NeuroStrip’s Sporting Edge

Animal Rules: The Island Pharmaceuticals Story (ILA)

Launching Armchair After Market

Compass Points North: Six-Month Psychedelic Data

The Capital Waterfall Starting to Flow?

A Fox got into the Cash Box: The Genetic Signatures Story (GSS)

The Armchair Analyst